Cicinelli E, Petruzzi D, Ragno G, Schönauer L M, Ruccia C, Matteo G
Department of Obstetrics and Gynecology, University of Bari, Italy.
Acta Obstet Gynecol Scand. 1996 Sep;75(8):730-3. doi: 10.3109/00016349609065736.
The objective of this study was to investigate the effectiveness of a single nasal spray administration of 0.8 mg bromocriptine in reducing PRL serum levels.
Eighteen physiologically hyperprolactemic women in the early days of puerperium were randomized to receive nasal bromocriptine or placebo; PRL serum levels were measured by RIA at 45, 30 and 15 minutes before the administration and after the following times: 15, 30, 45, 60, 120, 180, 240, 300, and 480 minutes.
After the administration of bromocriptine serum levels of PRL decreased rapidly; the reduction was statistically significant after 45 minutes. Four hours after the administration mean serum levels of PRL resulted in the normal range (< 20 micrograms/l); at the eighth hour the PRL levels were still normal. No one patient complained of any local or systemic side-effects.
Nasal route seems to be an effective and probably safe administration route for bromocriptine.
本研究的目的是调查单次鼻腔喷雾给予0.8毫克溴隐亭降低血清催乳素水平的有效性。
18名处于产褥期早期的生理性高催乳素血症女性被随机分为接受鼻腔溴隐亭或安慰剂治疗；在给药前45、30和15分钟以及给药后15、30、45、60、120、180、240、300和480分钟通过放射免疫分析法测量血清催乳素水平。
给予溴隐亭后血清催乳素水平迅速下降；45分钟后下降具有统计学意义。给药4小时后血清催乳素平均水平降至正常范围（<20微克/升）；在第8小时催乳素水平仍正常。没有患者抱怨任何局部或全身副作用。
鼻腔途径似乎是溴隐亭一种有效且可能安全的给药途径。
